EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing

Aayushi Srivastava, Diamanto Skopelitou, Beiping Miao, Sara Giagiobbe, Nagarajan Paramasivam, Abhishek Kumar, Chiara Diquigiovanni, Elena Bonora, Obul Reddy Bandapalli, Asta Försti iD, Kari Hemminki iD

European Journal of Endocrinology · 2025

DOI: 10.1093/ejendo/lvaf045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Endocrinology, 2025. Verfasst von Aayushi Srivastava und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Genetic Predisposition to Disease, Whole Genome Sequencing, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Czech Science Agency, National Institute for Cancer Research, NICR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Thyroid cancer (TC) is the most common endocrine malignancy, with 90%-95% of the cases representing non–medullary thyroid cancer (NMTC). Familial cases account only for a few of all cases and the underlying genetic causes are still poorly understood.

Methods

We whole-genome sequenced affected and unaffected members of an Italian NMTC family and applied our in-house developed Familial Cancer Variant Prioritization Pipeline (FCVPPv2) which prioritized 12 coding variants. We refined this selection using the VarSome American College of Medical Genetics and Genomics (ACMG) implementation, SNAP2 predictions and further in silico scores.

Results

We prioritized 4 possibly pathogenic variants in 4 genes including Ret proto-oncogene (RET), polypeptide N-acetylgalactosaminyltransferase 10 (GALNT10), ubinuclein-1 (UBN1), and prostaglandin I2 receptor (PTGIR). The role of RET point mutations in medullary thyroid carcinoma is well established. Similarly, somatic rearrangements of RET are known in papillary TC, a specific histotype of NMTC. In contrast to RET, no germline variants in PTGIR, GALNT10, or UBN1 have been linked to the development of TC to date. However, alterations in these genes have been shown to affect pathways related to cell proliferation, apoptosis, growth, and differentiation, as well as posttranslational modification and gene regulation. A thorough review of the available literature together with computational evidence supported the interpretation of the 4 shortlisted variants as possibly disease-causing in this family.

Conclusions

Our results implicate the first germline variant in RET in a family with NMTC as well as the first germline variants in PTGIR, GALNT10, and UBN1 in TC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsGenetic Predisposition to DiseaseWhole Genome SequencingCarcinoma, NeuroendocrineHumansProto-Oncogene MasMaleFemaleN-AcetylgalactosaminyltransferasesProto-Oncogene Proteins c-retPedigreeMiddle AgedAdultPolypeptide N-acetylgalactosaminyltransferase

Stichwörter der Autor:innen

GALNT10PTGIRRETUBN1familial non–medullary thyroid cancergermline variantwhole-genome sequencing

Substanzen

Proto-Oncogene MasN-AcetylgalactosaminyltransferasesMAS1 protein, humanProto-Oncogene Proteins c-retRET protein, humanPolypeptide N-acetylgalactosaminyltransferase

Autor:innen und Institutionen

  • Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
  • Heidelberg University, Medical Faculty, Heidelberg 69120, Germany.
  • Department of Medicine I and Clinical Chemistry, University Hospital of Heidelberg, Heidelberg 69120, Germany.
  • Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT), Heidelberg 69120, Germany.
  • Clinical Cooperation Unit Molecular Hematology-Oncology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
  • Unit of Medical Genetics, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40126, Italy.

ORCID-Profile: Asta Försti, Kari Hemminki

Förderung

  • Czech Science Agency
  • National Institute for Cancer Research
  • NICR
  • European Union-Next Generation EU
  • SALVAGE
  • European Union—Next Generation EU

Zitieren

APA

Srivastava, A., Skopelitou, D., Miao, B., Giagiobbe, S., Paramasivam, N., Kumar, A., Diquigiovanni, C., Bonora, E., Bandapalli, O. R., Försti, A., & Hemminki, K. (2025). Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvaf045

Vancouver

Srivastava A, Skopelitou D, Miao B, Giagiobbe S, Paramasivam N, Kumar A, et al. Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing. European Journal of Endocrinology. 2025. doi:10.1093/ejendo/lvaf045

BibTeX
@article{Srivastava2025,
  author = {Srivastava, Aayushi and Skopelitou, Diamanto and Miao, Beiping and Giagiobbe, Sara and Paramasivam, Nagarajan and Kumar, Abhishek and Diquigiovanni, Chiara and Bonora, Elena and Bandapalli, Obul Reddy and Försti, Asta and Hemminki, Kari},
  title = {Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing},
  journal = {European Journal of Endocrinology},
  year = {2025},
  doi = {10.1093/ejendo/lvaf045}
}
Kostenlos starten →